1
|
Briand F, Sencio V, Robil C, Heumel S, Deruyter L, Machelart A, Barthelemy J, Bogard G, Hoffmann E, Infanti F, Domenig O, Chabrat A, Richard V, Prévot V, Nogueiras R, Wolowczuk I, Pinet F, Sulpice T, Trottein F. Diet-Induced Obesity and NASH Impair Disease Recovery in SARS-CoV-2-Infected Golden Hamsters. Viruses 2022; 14:v14092067. [PMID: 36146875 PMCID: PMC9503118 DOI: 10.3390/v14092067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2022] [Revised: 09/12/2022] [Accepted: 09/14/2022] [Indexed: 01/08/2023] Open
Abstract
Obese patients with non-alcoholic steatohepatitis (NASH) are prone to severe forms of COVID-19. There is an urgent need for new treatments that lower the severity of COVID-19 in this vulnerable population. To better replicate the human context, we set up a diet-induced model of obesity associated with dyslipidemia and NASH in the golden hamster (known to be a relevant preclinical model of COVID-19). A 20-week, free-choice diet induces obesity, dyslipidemia, and NASH (liver inflammation and fibrosis) in golden hamsters. Obese NASH hamsters have higher blood and pulmonary levels of inflammatory cytokines. In the early stages of a SARS-CoV-2 infection, the lung viral load and inflammation levels were similar in lean hamsters and obese NASH hamsters. However, obese NASH hamsters showed worse recovery (i.e., less resolution of lung inflammation 10 days post-infection (dpi) and lower body weight recovery on dpi 25). Obese NASH hamsters also exhibited higher levels of pulmonary fibrosis on dpi 25. Unlike lean animals, obese NASH hamsters infected with SARS-CoV-2 presented long-lasting dyslipidemia and systemic inflammation. Relative to lean controls, obese NASH hamsters had lower serum levels of angiotensin-converting enzyme 2 activity and higher serum levels of angiotensin II—a component known to favor inflammation and fibrosis. Even though the SARS-CoV-2 infection resulted in early weight loss and incomplete body weight recovery, obese NASH hamsters showed sustained liver steatosis, inflammation, hepatocyte ballooning, and marked liver fibrosis on dpi 25. We conclude that diet-induced obesity and NASH impair disease recovery in SARS-CoV-2-infected hamsters. This model might be of value for characterizing the pathophysiologic mechanisms of COVID-19 and evaluating the efficacy of treatments for the severe forms of COVID-19 observed in obese patients with NASH.
Collapse
Affiliation(s)
| | - Valentin Sencio
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Cyril Robil
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Séverine Heumel
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Lucie Deruyter
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Arnaud Machelart
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Johanna Barthelemy
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Gemma Bogard
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Eik Hoffmann
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France
| | | | | | | | | | - Vincent Prévot
- Univ. Lille, INSERM, CHU Lille, Laboratory of Development and Plasticity of the Neuroendocrine Brain, Lille Neuroscience & Cognition, UMR-S 1172, European Genomic Institute for Diabetes (EGID), F-59000 Lille, France
| | - Ruben Nogueiras
- Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), S-15781 Santiago de Compostela, Spain
| | - Isabelle Wolowczuk
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Florence Pinet
- Univ. Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de Risque et Déterminants Moléculaires des Maladies Liées au Vieillissement, F-59000 Lille, France
| | | | - François Trottein
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France
- Correspondence:
| |
Collapse
|
2
|
Sencio V, Machelart A, Robil C, Benech N, Hoffmann E, Galbert C, Deryuter L, Heumel S, Hantute-Ghesquier A, Flourens A, Brodin P, Infanti F, Richard V, Dubuisson J, Grangette C, Sulpice T, Wolowczuk I, Pinet F, Prévot V, Belouzard S, Briand F, Duterque-Coquillaud M, Sokol H, Trottein F. Alteration of the gut microbiota following SARS-CoV-2 infection correlates with disease severity in hamsters. Gut Microbes 2022; 14:2018900. [PMID: 34965194 PMCID: PMC8726722 DOI: 10.1080/19490976.2021.2018900] [Citation(s) in RCA: 41] [Impact Index Per Article: 20.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Mounting evidence suggests that the gut-to-lung axis is critical during respiratory viral infections. We herein hypothesized that disruption of gut homeostasis during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may associate with early disease outcomes. To address this question, we took advantage of the Syrian hamster model. Our data confirmed that this model recapitulates some hallmark features of the human disease in the lungs. We further showed that SARS-CoV-2 infection associated with mild intestinal inflammation, relative alteration in intestinal barrier property and liver inflammation and altered lipid metabolism. These changes occurred concomitantly with an alteration of the gut microbiota composition over the course of infection, notably characterized by a higher relative abundance of deleterious bacterial taxa such as Enterobacteriaceae and Desulfovibrionaceae. Conversely, several members of the Ruminococcaceae and Lachnospiraceae families, including bacteria known to produce the fermentative products short-chain fatty acids (SCFAs), had a reduced relative proportion compared to non-infected controls. Accordingly, infection led to a transient decrease in systemic SCFA amounts. SCFA supplementation during infection had no effect on clinical and inflammatory parameters. Lastly, a strong correlation between some gut microbiota taxa and clinical and inflammation indices of SARS-CoV-2 infection severity was evidenced. Collectively, alteration of the gut microbiota correlates with disease severity in hamsters making this experimental model valuable for the design of interventional, gut microbiota-targeted, approaches for the control of COVID-19.Abbreviations: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; COVID-19, coronavirus disease 2019; SCFAs, short-chain fatty acids; dpi, day post-infection; RT-PCR, reverse transcription polymerase chain reaction; IL, interleukin. ACE2, angiotensin converting enzyme 2; TMPRSS2, transmembrane serine protease 2.
Collapse
Affiliation(s)
- Valentin Sencio
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000Lille, France,Centre National de la Recherche Scientifique (CNRS), UMR 9017, F-59000Lille, France,Institut National de la Santé et de la Recherche Médicale (Inserm) U1019, F-59000Lille, France,Centre Hospitalier Universitaire de Lille, F-59000Lille, France,Institut Pasteur de Lille, F-59000Lille, France
| | - Arnaud Machelart
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000Lille, France,Centre National de la Recherche Scientifique (CNRS), UMR 9017, F-59000Lille, France,Institut National de la Santé et de la Recherche Médicale (Inserm) U1019, F-59000Lille, France,Centre Hospitalier Universitaire de Lille, F-59000Lille, France,Institut Pasteur de Lille, F-59000Lille, France
| | - Cyril Robil
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000Lille, France,Centre National de la Recherche Scientifique (CNRS), UMR 9017, F-59000Lille, France,Institut National de la Santé et de la Recherche Médicale (Inserm) U1019, F-59000Lille, France,Centre Hospitalier Universitaire de Lille, F-59000Lille, France,Institut Pasteur de Lille, F-59000Lille, France
| | - Nicolas Benech
- Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, Gastroenterology department, F-75012Paris, France,Paris Center for Microbiome Medicine, Fédération Hospitalo-Universitaire, F-75012Paris, France
| | - Eik Hoffmann
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000Lille, France,Centre National de la Recherche Scientifique (CNRS), UMR 9017, F-59000Lille, France,Institut National de la Santé et de la Recherche Médicale (Inserm) U1019, F-59000Lille, France,Centre Hospitalier Universitaire de Lille, F-59000Lille, France,Institut Pasteur de Lille, F-59000Lille, France
| | - Chloé Galbert
- Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, Gastroenterology department, F-75012Paris, France,Paris Center for Microbiome Medicine, Fédération Hospitalo-Universitaire, F-75012Paris, France
| | - Lucie Deryuter
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000Lille, France,Centre National de la Recherche Scientifique (CNRS), UMR 9017, F-59000Lille, France,Institut National de la Santé et de la Recherche Médicale (Inserm) U1019, F-59000Lille, France,Centre Hospitalier Universitaire de Lille, F-59000Lille, France,Institut Pasteur de Lille, F-59000Lille, France
| | - Séverine Heumel
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000Lille, France,Centre National de la Recherche Scientifique (CNRS), UMR 9017, F-59000Lille, France,Institut National de la Santé et de la Recherche Médicale (Inserm) U1019, F-59000Lille, France,Centre Hospitalier Universitaire de Lille, F-59000Lille, France,Institut Pasteur de Lille, F-59000Lille, France
| | - Aline Hantute-Ghesquier
- Institut Pasteur de Lille, F-59000Lille, France,Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER – Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000Lille, France
| | - Anne Flourens
- Institut Pasteur de Lille, F-59000Lille, France,Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER – Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000Lille, France
| | - Priscille Brodin
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000Lille, France,Centre National de la Recherche Scientifique (CNRS), UMR 9017, F-59000Lille, France,Institut National de la Santé et de la Recherche Médicale (Inserm) U1019, F-59000Lille, France,Centre Hospitalier Universitaire de Lille, F-59000Lille, France,Institut Pasteur de Lille, F-59000Lille, France
| | | | | | - Jean Dubuisson
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000Lille, France,Centre National de la Recherche Scientifique (CNRS), UMR 9017, F-59000Lille, France,Institut National de la Santé et de la Recherche Médicale (Inserm) U1019, F-59000Lille, France,Centre Hospitalier Universitaire de Lille, F-59000Lille, France,Institut Pasteur de Lille, F-59000Lille, France
| | - Corinne Grangette
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000Lille, France,Centre National de la Recherche Scientifique (CNRS), UMR 9017, F-59000Lille, France,Institut National de la Santé et de la Recherche Médicale (Inserm) U1019, F-59000Lille, France,Centre Hospitalier Universitaire de Lille, F-59000Lille, France,Institut Pasteur de Lille, F-59000Lille, France
| | | | - Isabelle Wolowczuk
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000Lille, France,Centre National de la Recherche Scientifique (CNRS), UMR 9017, F-59000Lille, France,Institut National de la Santé et de la Recherche Médicale (Inserm) U1019, F-59000Lille, France,Centre Hospitalier Universitaire de Lille, F-59000Lille, France,Institut Pasteur de Lille, F-59000Lille, France
| | - Florence Pinet
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, F-59000Lille, France
| | - Vincent Prévot
- Univ. Lille, Inserm, CHU Lille, UMR-S1172, EGID and DISTALZ, F-59000Lille, France
| | - Sandrine Belouzard
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000Lille, France,Centre National de la Recherche Scientifique (CNRS), UMR 9017, F-59000Lille, France,Institut National de la Santé et de la Recherche Médicale (Inserm) U1019, F-59000Lille, France,Centre Hospitalier Universitaire de Lille, F-59000Lille, France,Institut Pasteur de Lille, F-59000Lille, France
| | | | - Martine Duterque-Coquillaud
- Institut Pasteur de Lille, F-59000Lille, France,Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER – Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000Lille, France
| | - Harry Sokol
- Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, Gastroenterology department, F-75012Paris, France,Paris Center for Microbiome Medicine, Fédération Hospitalo-Universitaire, F-75012Paris, France,Institut National de la Recherche Agronomique (INRAE), UMR1319 Micalis & AgroParisTech, F-78350Jouy en Josas, France
| | - François Trottein
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000Lille, France,Centre National de la Recherche Scientifique (CNRS), UMR 9017, F-59000Lille, France,Institut National de la Santé et de la Recherche Médicale (Inserm) U1019, F-59000Lille, France,Centre Hospitalier Universitaire de Lille, F-59000Lille, France,Institut Pasteur de Lille, F-59000Lille, France,CONTACT François Trottein Institut Pasteur de Lille, 1 rue du Professeur Calmette, Lille 59000
| |
Collapse
|